MV-NIS

MV-NIS is the Edmonston vaccine strain of measles virus, genetically rewired to also express the thyroid's iodide pump (NIS) so doctors can image where the virus goes by SPECT scan. Mayo Clinic has been testing this platform for two decades across multiple myeloma, ovarian cancer, and pediatric brain tumors. NCT02068794 specifically loads the virus inside adipose-derived mesenchymal stem cells (MSCs) - used as a cellular taxi - and administers them by intraperitoneal (IP) infusion to women with recurrent ovarian, peritoneal, or fallopian tube cancer [1]. The IP route is the design's first defense against the neutralizing-antibody problem: roughly 90% of adults carry anti-measles IgG from MMR vaccination, and naked virus delivered IV is cleared within minutes of infusion [2]. IP delivery substantially reduces that exposure by bypassing systemic circulation, but neutralizing antibodies are also present in peritoneal fluid, which is why Mayo still layered MSC encapsulation on top - a belt-and-suspenders approach borrowed from the IV myeloma program where the antibody problem is far more acute. This program matters not because anyone expects MV-NIS to be the next blockbuster, but because it is one of the few human datasets on whether oncolytic virotherapy can work against a vaccinated population - the question that determines whether the field beyond intratumoral T-VEC has commercial legs.

MV-NIS remains investigational worldwide. No measles-based oncolytic has ever reached approval anywhere. NCT02068794 is a Phase 1/2 dose-escalation/expansion study sponsored by Mayo Clinic with no disclosed pharma partner; the trial has been open since 2014 [1]. The most recent posted protocol version is dated 22 March 2024 (MC1266), indicating the trial remained active under amendment at that point; no ClinicalTrials.gov-listed primary completion date could be confirmed in the public record as of this writeup, and Mayo has not issued public guidance on an interim analysis. No FDA breakthrough designation, fast track, accelerated approval pathway, or orphan designation has been publicly announced. The most recent peer-reviewed MV-NIS clinical readout came from the PNOC005 trial in pediatric medulloblastoma and atypical teratoid/rhabdoid tumors, published in Clinical Cancer Research in 2025, which extends the Edmonston-NIS platform to a new patient group but operates separately from the ovarian protocol [3]. The Mayo spinout Vyriad licenses the Edmonston-NIS platform; its most recent disclosed corporate event was the close of a final $25M tranche of its Series B on 23 December 2025, bringing the round to $85M total, with the financing directed at an in vivo CAR-T candidate (VV169) in multiple myeloma rather than ovarian cancer [7]. The drug carries RxNorm CUI 746175 under the canonical name MV-NIS but has no NDA/BLA file. Treat the regulatory status as 'academic Phase 2 with no clear path to registration absent a commercial partner.'

The Edmonston vaccine strain attaches to CD46, a complement-regulatory protein elevated on the surface of many solid tumor types, including ovarian carcinoma and multiple myeloma. Tumor cells overexpress CD46 to shield themselves from complement attack; the same upregulation makes them measles-bait. The receptor distinction matters: wild-type measles uses SLAM (signaling lymphocyte activation molecule) expressed on immune cells, which drives the systemic infection and immunosuppression of natural measles. The Edmonston vaccine strain, by contrast, was passaged into receptor flexibility and now also engages CD46, which is broadly expressed on epithelia and overexpressed on many tumors - this is why the vaccine strain preferentially infects tumor tissue over normal lymphoid tissue and why it has a different safety profile than wild-type virus. Once inside, the virus replicates, fuses neighboring cells into giant multinucleated masses called syncytia, and kills them. The added NIS gene - the thyroid's iodide channel - lets clinicians dose patients with radioactive iodine and image exactly where the virus is replicating on SPECT. It also opens the door to radio-virotherapy: deliver therapeutic I-131 once you know the virus is concentrated at tumor sites. The validation case for this platform is thin but real. The Phase 1 multiple myeloma study by Dispenzieri at Mayo showed dose-dependent viral replication and clinical activity at the highest dose, including a widely-cited complete remission in one patient [2]. Translational work demonstrated that measles infection induced tumor-antigen-specific T-cell responses, supporting a mechanism beyond direct lysis: turning a cold tumor hot [4]. The PNOC005 pediatric readout added in vivo evidence for intratumoral virus delivery and immune engagement in CNS tumors [3]. What has never been demonstrated in a controlled fashion: durable, reproducible objective responses across an unselected, vaccinated patient population. Mechanism is biologically interesting; whether it is a drug is still an open question.

NCT02068794 is a single-arm Phase 1/2 trial in women with recurrent ovarian, primary peritoneal, or fallopian tube cancer who have failed platinum-based chemotherapy [1]. Patients receive intraperitoneal infusions of MV-NIS-loaded adipose-derived mesenchymal stem cells; the MSCs serve as a Trojan horse to shield the virus from neutralizing antibodies and concentrate delivery in the peritoneal cavity, where ovarian cancer spreads. Protocol documentation describes the MSCs as adipose-tissue-derived but the registry record does not unambiguously specify whether they are autologous or allogeneic at expansion-dose scale - a meaningful gap because allogeneic banking would be the only route to a commercially scalable product, while autologous prep ties manufacturing to a single patient's procurement. The Phase 1 portion uses standard 3+3 dose escalation with primary endpoints of maximum tolerated dose and dose-limiting toxicity. The Phase 2 portion's primary endpoints are objective response rate by RECIST (Response Evaluation Criteria in Solid Tumors - a standardized imaging-based measurement of tumor shrinkage) and progression-free survival. There is no active comparator arm: heavily pretreated platinum-resistant ovarian patients have limited standard options, so a single-arm signal is defensible for a Phase 2. Concerns about the design: the trial opened in 2014 and has run more than 11 years without a primary publication, suggesting slow accrual or weak interim signal; it is single-center, limiting generalizability; there is no biomarker selection for CD46 expression or baseline measles antibody titer, both of which should predict response; and the MSC manufacturing is bespoke to Mayo, which constrains any pharma-led replication. None of these flaws kill the science, but they cap how much external observers can infer from an eventual readout.

Our model estimates a 6% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design and its light or open-label blinding; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk dominates. Roughly 90% of adults carry anti-measles IgG from MMR vaccination, and naked virus delivered IV is cleared within minutes [2]. The MSC carrier hypothesis is biologically sound but unproven at clinical scale: Mayo's own preclinical work suggests MSCs deliver virus to tumor, but no published human data confirms that delivery translates to higher intratumoral viral titers than direct injection. Intraperitoneal administration partially sidesteps the antibody problem by avoiding systemic circulation, but locoregional delivery limits the addressable disease. Safety risk is moderate: vaccine-strain measles is well-tolerated in healthy adults, but persistent infection in immunosuppressed cancer patients and the unknown behavior of MSC-protected virus in vivo warrant caution. Execution risk is the elephant in the room: 11+ years of enrollment at a single center without a published primary readout is a yellow flag that the trial is either underpowered, undersignaled, or both. Manufacturing risk is severe: every dose requires fresh MSCs infected with GMP-grade measles virus, a workflow no commercial entity has scaled, and the autologous-vs-allogeneic ambiguity in the public record compounds that. Commercial risk is the killer. Recurrent ovarian cancer is now contested by PARP inhibitors in BRCA/HRD-positive disease - homologous recombination deficiency, a DNA-repair defect that predicts PARP inhibitor response - by mirvetuximab soravtansine (Elahere) in FRα-high tumors (US sales >$470M in 2024), and by a wave of emerging ADCs that analysts project will be the top-selling ovarian cancer class by 2034 [8]. A single-arm Phase 2 response signal in heavily pretreated patients will not displace any of them without a randomized confirmatory trial that Mayo alone cannot fund.

Watch but don't bet. MV-NIS is the most data-rich human program for systemic oncolytic measles, and the platform has academic credibility through Mayo, the PNOC consortium, and a long publication trail [2][3][4][5]. The signal worth watching is the PNOC005 pediatric follow-up data: if the medulloblastoma and ATRT responses hold and deepen, the ovarian program borrows credibility by association [3]. The specific data point that would change the assessment for ovarian cancer: an objective RECIST response in a measles-seropositive patient with confirmed intratumoral viral replication on NIS SPECT imaging. That has never been demonstrated. Tracking anchors: (a) Mayo's eventual primary publication for NCT02068794 - protocol active under March 2024 amendment, but no public completion guidance; (b) Vyriad's next corporate disclosure beyond the December 2025 Series B close, particularly any pharma licensing of the measles-NIS platform rather than the in vivo CAR-T program that absorbed the latest funding [7]; (c) the PNOC005 follow-up publication cycle. The realistic outcome is that MV-NIS becomes a methodological footnote: a platform that validated CD46 tropism and NIS-based viral imaging but didn't crack the neutralizing-antibody problem at clinical scale. The sharper question for investors isn't whether MV-NIS clears Phase 2; it's whether the next generation of armed oncolytic viruses - Replimune's RP1 (vusolimogene oderparepvec) and RP2, CG Oncology's cretostimogene, and pelareorep's reovirus platform - learned the right lessons from a decade of Mayo's academic data. MV-NIS is more valuable as a teaching dataset than as a commercial asset.